Five Lives Secures Funding to Develop Smartphone-Based Alzheimer's Prevention Platform
French healthtech startup Five Lives has raised €3.5 million in a seed funding round to advance its mission of transforming smartphones into tools for brain health monitoring and Alzheimer's disease risk reduction. The round was led by Sharpstone Capital, with participation from HCVC, Kima Ventures, and several business angels.
The company is developing a scientifically validated mobile application designed as a digital therapeutic. Its core function is to assess and help mitigate key modifiable risk factors associated with cognitive decline and dementia, such as hypertension, diabetes, hearing loss, depression, and social isolation. The app provides users with personalized, actionable recommendations based on their assessment.
This funding will accelerate the platform's development and support clinical validation efforts. Five Lives is currently conducting a clinical study in France involving 150 participants aged 60 and over, in partnership with the CoBTeK laboratory at the Université Côte d'Azur and the Centre Mémoire de Ressources et de Recherche (CMRR) in Nice. The study aims to evaluate the app's impact on users' risk profiles and its correlation with traditional cognitive tests.
Founded by CEO Chloé Savignac and Chief Scientific Officer Chloé Lelong, Five Lives operates on the premise that up to 40% of dementia cases could be prevented or delayed by addressing modifiable lifestyle and health factors. The startup's approach aims to provide a scalable, accessible, and proactive alternative to traditional, often reactive, memory clinic consultations, which are frequently burdened by long wait times.
The new capital will also be used to prepare for a commercial launch in France and the UK, with the goal of making the application available to the public in 2025.